Trial Profile
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions
- Acronyms PCR-MIB
- 13 Sep 2022 Results of safety and efficacy , presented at the 47th European Society for Medical Oncology Congress
- 14 Feb 2022 Planned primary completion date changed from 1 Sep 2023 to 31 Mar 2022.
- 14 Feb 2022 Status changed from recruiting to active, no longer recruiting.